Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol

High grade astrocytic glioma (HGG) is a lethal solid malignancy with high recurrence rates and limited survival. While several cytotoxic agents have demonstrated efficacy against HGG, drug sensitivity testing platforms to aid in therapy selection are lacking. Patient-derived organoids (PDOs) have be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2024-07, Vol.19 (7), p.e0307818
Hauptverfasser: Toh, Tan Boon, Thng, Dexter Kai Hao, Bolem, Nagarjun, Vellayappan, Balamurugan A, Tan, Bryce Wei Quan, Shen, Yating, Soon, Sou Yen, Ang, Yvonne Li En, Dinesh, Nivedh, Teo, Kejia, Nga, Vincent Diong Weng, Low, Shiong Wen, Khong, Pek Lan, Chow, Edward Kai-Hua, Ho, Dean, Yeo, Tseng Tsai, Wong, Andrea Li Ann
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!